[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@plainyogurt21 Avatar @plainyogurt21 Adu Subramanian

Adu Subramanian posts on X about $fbrx, $mbx, $srrk, banking the most. They currently have XXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence stocks XXXX% finance XXX% cryptocurrencies XXX%

Social topic influence $fbrx #1, $mbx 0.5%, $srrk 0.5%, banking 0.5%, stocks 0.5%, number of 0.5%, $nrix 0.5%, $anab 0.5%, tha 0.5%, $uthr XXX%

Top accounts mentioned or mentioned by @houndcl @amaymd @synapsesurfer @avidresearch @a_may_md @joserestonva @sanctuarybio @barry3252181 @jfais20 @ejliv850 @melvinriskmgmt @biotenic @masonat7 @seedy19tron @expatdave34 @persimmonti @dmitrykovalchuk @synapse_surfer @svixenjoyoor @nociftw

Top assets mentioned Marblex (MBX) Scholar Rock Holding Corporation Common Stock (SRRK) United Therapeutics, Corp. (UTHR) Novo-Nordisk (NVO) SPDR S&P XXX ETF Trust (SPY) Bitcoin Incognito (XBI) ARK Innovation ETF (ARKK) Bitcoin (BTC)

Top Social Posts #

Top posts by engagements in the last XX hours

"@houndcl @realchinesespy $MBX and $SRRK have given me brain damage this year"
X Link @plainyogurt21 2025-10-14T23:43Z 4872 followers, XXX engagements

"@MartinShkreli @litcapital IB vs Buyside mentality More output = win in Banking Not true for anyone actually buying stocks So the value of doing more work is key for certain people"
X Link @plainyogurt21 2025-10-17T10:36Z 4870 followers, XXX engagements

"@PCM_bio @masonat7 @SnupSnus @PersimmonTI Oral PCSK9 only potential competition d/t eligibility constraints for Lp(a). Isolated LDL effects of PCSK9 and oral nature of obi. Oral drugs = PCP can use it easier. Selling point on AD matters for patients. (the number of pts who don't want lipitor cuz of 🧠 effects is odd)"
X Link @plainyogurt21 2025-10-14T22:30Z 4868 followers, XXX engagements

"@BayAreaBiotechI Here's the PK data I could find out there"
X Link @plainyogurt21 2025-10-15T02:58Z 4870 followers, XXX engagements

"@peter_mantas $nrix is there a specific reason you think better than beigene"
X Link @plainyogurt21 2025-10-03T10:39Z 4868 followers, XXX engagements

"$FBRX $ANAB Based on that PK data and teh IC50 data from the ANAB presentation here's the numbers I get for 3mg/kg Cmax 100ug/ML Ctrough 60ug/ML = 400nM IC90 = 300-1000nm for T cells (CD8 and CD4). This get's close on low dose. And the SC formulation in the Phase X study is up to XXX mg/kg (makes some sense due to volume limits in injections) Tha low dose is borderline the phase 2b. THe subcu dosing doesn't have MAD data on PK nor does it specifify dosing in the phase 2b. We can plug in whatever numbers and thats approximately true. I want to see more PK and PD data from them to be certain"
X Link @plainyogurt21 2025-10-15T03:32Z 4872 followers, 1547 engagements

"@ExpatDave34 @svix_enjoyoor $UTHR CEO has made a huge difference in a lot of people's lives personally inspired by her daughter's diagnosis. Yes recent actions favor UTHR vs competition but she built (in part) the PAH market"
X Link @plainyogurt21 2025-10-09T16:50Z 4870 followers, XX engagements

"$NVO $FULC NDEC trial Over enrolled and completed July 2025. May see results ASh 2025 later this year"
X Link @plainyogurt21 2025-10-15T14:24Z 4872 followers, 1624 engagements

"@PCM_bio @masonat7 @SnupSnus @PersimmonTI Okay we agree completely then. My target acquirer was actually Pfizer. CV presence without next gen approach. Maybe a Bayer"
X Link @plainyogurt21 2025-10-14T22:49Z 4869 followers, XXX engagements

"$FBRX kinda cooked based on worse PK binding. (IV dosing)"
X Link @plainyogurt21 2025-10-14T20:47Z 4872 followers, 4654 engagements

"$SPY: XX% $XBI: X% $ARKK: XX% $BTC: XX% Biotech remains and will always remain a stock pickers market. If you're feeling FOMO today or in the last few months just know these opportunities happen EVERY YEAR. OVER AND OVER. Nature of biotech"
X Link @plainyogurt21 2025-09-24T20:38Z 4870 followers, 6184 engagements

"@MattBiotech improvements in fatigue" - where do you see that it's better on fatigue @EpochSwing had a good opinion here: and it's bold of you to assume they can get competent management. It's just a hard sell it seems"
X Link @plainyogurt21 2025-10-15T19:34Z 4870 followers, XXX engagements